Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Placebo; Biological: Mepolizumab Sponsors: GlaxoSmithKline; PPD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Research